| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |